Renal Handling of 99mTc-Labeled Antibody Fab Fragments with a Linkage Cleavable by Enzymes on Brush Border Membrane.

The high and persistent renal radioactivity levels after injection of radiolabeled low-molecular-weight polypeptides constitute a significant problem for their diagnostic and therapeutic applications, especially when they are labeled with metallic radionuclides. To improve the renal radioactivity levels of technetium-99m (99mTc)-labeled Fab fragments, a mercaptoacetyltriglycine (MAG3)-based new bifunctional chelating agent with a cleavable glycyl-phenylalanyl-lysine (GFK) linkage, MAG3-GFK-suc-TFP, was designed, synthesized, and evaluated. 99mTc-labeled Fab was obtained by reacting MAG3-GFK-Fab conjugate with 99mTc-glucarate. The GFK linkage remained stable in plasma but was cleaved by enzymes on the renal brush border membrane. The comparative biodistribution studies with indium-111 (111In)-labeled Fab using SCN-CHX-A″-DTPA showed that while both radiolabeled Fabs exhibited similar elimination rates from the blood, [99mTc]Tc-MAG3-GFK-Fab registered much lower renal radioactivity levels from 30 min post-injection onward due to the release and subsequent urinary excretion of [99mTc]Tc-MAG3-Gly. However, [99mTc]Tc-MAG3-GFK-Fab showed an increase in the intestinal radioactivity levels with the time that was not observed with 111In-labeled Fab. The analysis of the intestinal contents suggested the redistribution of [99mTc]Tc-MAG3-Gly to the intestine. The retrospective comparison of [99mTc]Tc-MAG3-GFK-Fab with the radiolabeled Fabs so far prepared under the identical concept suggested that some portion of [99mTc]Tc-MAG3-Gly was generated after the coated vesicle formation and they were excreted into the blood, and subsequently redistributed in the intestine via hepatobiliary excretion. In conclusion, MAG3-GFK-suc-TFP provided 99mTc-labeled Fabs that exhibit low renal radioactivity shortly after injection by the post-labeling procedure. The present study indicated that, contrary to our earlier proposal, the generation of the radiometabolites would proceed not only during the internalization process of the parental antibody fragments but also after coated vesicle formation. This study also showed that the intracellular behaviors of radiometabolites played crucial roles in the elimination rates and the routes of the radioactivity from the kidney.

[1]  H. Hatakeyama,et al.  Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models , 2020, Journal for ImmunoTherapy of Cancer.

[2]  Xinming Zhao,et al.  Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma Xenografts , 2019, Investigational New Drugs.

[3]  L. Carroll,et al.  Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications , 2018, ChemMedChem.

[4]  T. Uehara,et al.  Preferential Cleavage of a Tripeptide Linkage by Enzymes on Renal Brush Border Membrane To Reduce Renal Radioactivity Levels of Radiolabeled Antibody Fragments. , 2018, Journal of medicinal chemistry.

[5]  J. Löfblom,et al.  Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules , 2018, Amino Acids.

[6]  A. Scott,et al.  Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a , 2016, The Journal of Nuclear Medicine.

[7]  R. Boellaard,et al.  89Zr-cetuximab PET imaging in patients with advanced colorectal cancer , 2015, Oncotarget.

[8]  G. Koning,et al.  A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[9]  H. Hanaoka,et al.  (67/68)Ga-labeling agent that liberates (67/68)Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels. , 2014, Bioconjugate chemistry.

[10]  S. Muyldermans,et al.  Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody , 2014, Theranostics.

[11]  Atsushi B. Tsuji,et al.  Development of positron emission tomography probe of 64Cu-labeled anti-C-kit 12A8 Fab to measure protooncogene C-kit expression. , 2011, Nuclear medicine and biology.

[12]  H. Lundqvist,et al.  The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  K. Endo,et al.  Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels. , 2007, Bioconjugate chemistry.

[14]  H. Saji,et al.  In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels. , 2005, Bioconjugate chemistry.

[15]  A. Wu,et al.  Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. , 2002, Bioconjugate chemistry.

[16]  T. Saga,et al.  Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments. , 2001, Bioconjugate chemistry.

[17]  H. Sakahara,et al.  Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications. , 1996, Bioconjugate chemistry.

[18]  H. Sakahara,et al.  Maleimidoethyl 3-(tri-n-butylstannyl)hippurate: a useful radioiodination reagent for protein radiopharmaceuticals to enhance target selective radioactivity localization. , 1994, Journal of medicinal chemistry.

[19]  M. Nedelman,et al.  Enhanced kidney clearance with an ester-linked 99mTc-radiolabeled antibody Fab'-chelator conjugate. , 1990, Bioconjugate chemistry.

[20]  R. Michalides,et al.  Genetic marker patterns and endogenous mammary tumor virus genes in inbred mouse strains of Japan. , 1986, Jikken dobutsu. Experimental animals.